Absci Corp. (ABSI) has drawn attention with compelling preclinical data for its lead program, ABS-201, an AI-designed antibody targeting the prolactin receptor. The recent findings demonstrated that ABS-201 stimulates hair growth by regenerating the stem cell niche and promoting key growth modulators in translational human scalp models.
With the Phase 1/2a HEADLINE trial now underway and interim results anticipated in 2026, Absci is positioning ABS-201 as a potential breakthrough therapy for androgenetic alopecia, a condition affecting millions with limited treatment options.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com